XML 38 R31.htm IDEA: XBRL DOCUMENT v3.26.3
Summary of Significant Accounting Policies - Schedule of Significant Segment Expenses (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Total operating expenses $ 21,672     $ 19,070     $ 65,722 $ 61,767
Loss from operations (21,672)     (19,070)     (65,722) (61,767)
Other income, net 714     1,047     2,694 3,680
Change in fair value of warrant liabilities 17,025     564     (11,560) 22,917
Net loss (3,933) $ (31,630) $ (39,025) (17,459) $ (11,216) $ (6,495) (74,588) (35,170)
Operating Segments [Member]                
Segment Reporting [Line Items]                
Tegoprubart - kidney transplantation programs 6,526     9,363     17,632 26,600
Tegoprubart - other development programs 0     0     0 (168)
Manufacturing 6,867     1,736     21,814 11,031
Personnel-related expenses 4,323     3,664     12,221 10,808
Stock-based compensation 1,924     2,428     7,280 7,986
Other segment items 2,032     1,879     6,775 5,510
Total operating expenses 21,672     19,070     65,722 61,767
Loss from operations (21,672)     (19,070)     (65,722) (61,767)
Other income, net 714     1,047     2,694 3,680
Change in fair value of warrant liabilities 17,025     564     (11,560) 22,917
Net loss $ (3,933)     $ (17,459)     $ (74,588) $ (35,170)